Background/Aims: Obstructive jaundice due to intraductal tumour growth is a rare symptom in association with hepatocellular carcinoma (HCC). Methods: We report a 65-year-old white male who was admitted to our department with a 2-week history of progressive jaundice. At laparotomy, the liver showed advanced cirrhosis due to long-standing biliary obstruction. Cholangiography confirmed total obstruction of the main bifurcation of the hepatic duct by intraductal tumour growth. Combination treatment with surgical segment III drainage, transcatheter arterial embolization and radioembolization with yttrium-90 resin particles and endoscopic stenting was performed. This form of treatment has never been reported before. Results: With these combined procedures, relief of jaundice and a survival time of 32 months could be achieved. Conclusion: The combination of palliative methods may relieve jaundice, ensure a good quality of life and possibly prolong survival in patients with mechanical tumour obstruction of the biliary tree by HCC.

Duvoux C, Rahmouni A, Mathieu D, Dhuneaux D: Symptomatologie clinique et aspects radiologiques des cancers primitifs du foie. Rev Prat 1992;42:1628–1634.
Maurer ChA, Dyong Th, Baer HU: Der segmentale Gallengang-Bypass bei Obstruktion im Leberhilus: nur eine Alternative? Chirurg 1995;66:794–799.
Matthews JB, Baer HU, Schweizer WP, Gertsch P, Carrel T, Blumgart LH: Recurrent cholangitis with and without anastomotic stricture after biliary-enteric bypass. Arch Surg 1993;128:269–272.
Glättli A, Stain SC, Baer HU, Schweizer W, Triller J, Blumgart LH: Unresectable malignant biliary obstruction: Treatment by self-expandable biliary endoprostheses. HPB Surg 1993;6:175–184.
Ducreux M, Liguory Cl, Lefebvre JF, Ink O, Choury A, Fritsch J, Bonnel D, Derhy S, Etienne JP: Management of malignant hilar biliary obstruction by endoscopy: Results and prognostic factors. Dig Dis Sci 1992;37:778–783.
Lee MJ, Mueller PR, Dawson SL, Gazelle SL, Hahn PF, Goldberg MA, Boland GW: Percutaneous ethanol injection for the treatment of hepatic tumors: indications, mechanisms of action, technique, and efficacy. Am J Roentgenol 1995;164:215–220.
Kotoh K, Sakai H, Morotomi I, Nawata H: The use of percutaneous ethanol injection therapy for recurrence of hepatocellular carcinoma. Hepatogastroenterology 1995;42:197–200.
Pirschel J, Lauchart W: Die Chemoembolisation des inoperablen hepatozellulären Karzinoms: ein chirurgisch-radiologisches Therapiekonzept. Helv Chir Acta 1990;57:889–893.
Chung JW, Park JH, Han JK, Choi BI, Han MC: Hepatocellular carcinoma and portal vein invasion: Results of treatment with transcatheter oily chemoembolization. Am J Roentgenol 1995;165:315–321.
Park JH, Han JK, Chung JW, Choi BI, Han MC, Kim YI: Superselective transcatheter arterial embolization with ethanol and iodized oil for hepatocellular carcinoma. J Vasc Interv Radiol 1993;4:333–339.
Couinaud C: Le foie. Etudes anatomiques et chirurgicales. Paris, Masson, 1957.
Baer HU, Holzinger F, Dennison AR, Zimmermann A: Diagnosis and surgical therapy of dependent and pedunculated hepatic tumours. Dig Surg 1995;12:228–234.
Bismuth H, Corlette MB: Intrahepatic cholangioenteric anastomosis in carcinoma of the hilus of the liver. Surg Gynecol Obstet 1975;140:170–178.
Choi TK, Fan ST, Lai ECS, Wong J: Malignant hilar biliary obstruction treated by segmental bilioenteric anastomosis. Surgery 1988;104:525–529.
Longmire WP, Sanford MC: Intrahepatic cholangiojejunostomy with partial hepatectomy for biliary obstruction. Surgery 1948;24:264–276.
Shepherd FA, Rotstein LE, Yip TCK, Sniderman KW: A phase I dose escalation trial of yttrium-90 microspheres in the treatment of primary hepatocellular carcinoma. Cancer 1992;70:2250–2254.
Houle S, Yip TCK, Shepherd FA, Rotstein LE, Sniderman KW, Theis E, Cawthorn RH, Richmond-Cox K: Hepatocellular carcinoma: Pilot trial of treatment with yttrium-90 microspheres. Radiology 1989;172:857–860.
Triller J, Baer HU, Geiger L, Kinser J, Rösler H, Blumgart LH: Radioembolisation of hepatocellular carcinoma with yttrium-90 resin particles. Eur J Radiol 1995;5:603–608.
Triller J, Rösler H, Geiger L, Baer HU: Methodik der superselektiven Radioembolisation von Lebertumoren mit Yttrium-90-Resin-Partikeln. Fortschr Geb Röntgenstr Nuklearmed 1994;160:425–431.
Kappel DA, Miller DR: Primary hepatic carcinoma: A review of thirty-seven patients. Am J Surg 1972;124:798–802.
Ihde DC, Sherlock P, Winawer SJ, Fortner JG: Clinical manifestations of hepatoma: A review of 6 years’ experience at a cancer hospital. Am J Med 1974;56:83–91.
Okuda K: Clinical aspects of hepatocellular carcinoma: analysis of 134 cases; in Okuda K, Peters RL (eds): Hepatocellular Carcinoma. New York, Wiley, 1976, pp 387–436.
Lin TY, Chen KM, Chen YR, Lin WSJ, Wang TH, Sung JL: Icteric type hepatoma. Med Chir Dig 1975;4:267–270.
Lee NW, Wong KP, Siu KF, Wong J: Cholangiography in hepatocellular carcinoma with obstructive jaundice. Clin Radiol 1984;35:119–123.
Kojiro M, Kawabata K, Kawano Y, Shirai F, Takemoto N, Nakashima T: Hepatocellular carcinoma presenting as intrabile duct tumor growth: A clinicopathologic study of 24 cases. Cancer 1982;49:2144–2147.
Tsuzuki T, Sugioka A, Ueda M, Iida S, Kanai T, Yoshii H, Nakayasu K: Hepatic resection for hepatocellular carcinoma. Surgery 1990;107:511–520.
Tanoue K, Kanematsu T, Matsumata T, Shirabe K, Sugimachi K: Successful surgical treatment of hepatocellular carcinoma invading into biliary tree. HPB Surg 1991;4:237–244.
Van Sonnenberg E, Ferrucci JT: Bile duct obstruction in hepatocellular carcinoma (hepatoma) – clinical and cholangiographic characteristics: Report of 6 cases and review of the literature. Radiology 1979;130:7–13.
Terada T, Nakanuma Y, Kawai K: Small hepatocellular carcinoma presenting as intrabiliary pedunculated polyp and obstructive jaundice. J Clin Gastroenterol 1989;11:578–583.
Afroudakis A, Bhuta SM, Ranganath KA, Kaplowitz N: Obstructive jaundice caused by hepatocellular carcinoma: Report of three cases. Am J Dig Dis 1978;23:609–617.
Buckmaster MJ, Schwartz RW, Carnahan GE, Strodel WE: Hepatocellular carcinoma embolus to the common hepatic duct with no detectable primary hepatic tumor. Am Surg 1994;60:699–702.
Vagianos C, Karavias D, Dragotis C, Kalofonos H, Androulakis J: Obstructive jaundice due to intracholedochal blood clot: An unusual early presentation of primary hepatic carcinoma. Br J Clin Pharmacol 1993;47:222–223.
Lau WY, Leung JWC, Li AKC: Management of hepatocellular carcinoma presenting as obstructive jaundice. Am J Surg 1990;160:280–282.
Friedman MA: Primary hepatocellular cancer: Present results and future prospects. Int J Radiat Oncol Biol Phys 1983;9:1841–1850.
London WT: Primary hepatocellular carcinoma: Etiology, pathogenesis, and prevention. Hum Pathol 1981;12:1085–1097.
Chen MF, Jan YY, Jeng LB, Hwang TL, Wang CS, Chen SC: Obstructive jaundice secondary to ruptured hepatocellular carcinoma into the common bile duct: Surgical experiences of 20 cases. Cancer 1994;73:1335–1340.
Tomita T, Ooyama R, Maruya I, Takahashi H, Fujita H, Shimazu H: Report on unusual mode of recurrence occurring five years after left hepatic lobectomy in a patient with icteric type hepatoma. Jpn J Gastrointest Surg 1981;14:495–500.
Beazley RM, Hadjis N, Benjamin IS, Blumgart LH: Clinicopathological aspects of high bile duct cancer: Experience with resection and bypass surgical treatments. Ann Surg 1984;199:623–634.
Okuda K, Peters RL, Simson IW: Gross anatomic features of hepatocellular carcinoma from three disparate geographic areas. Proposal of new classification. Cancer 1984;54:2165–2173.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.